Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of PF-06823859 in adult dermatomyositis
2021-004787-10Phase 2Completed
- Sponsor
- Pfizer
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dazukibart in dermatomyositis (DM), sponsored by Pfizer. Primary endpoints: Incidence of adverse events, Laboratory abnormalities and 2 more. Started Dec 2021; status: completed.
02
Drugs
dazukibart
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on 2021-004787-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004787-10.